Track record · closed signal

Innoviva Inc (INVA) — closed signal from May 13, 2026

Partial Published before the outcome was known, scored automatically when the window closed on August 11, 2026 — -9.4% at the close.

Predicted vs. what happened

INVA price · publication thesis → realized outcomesplit-adjusted

$22.00 – $23.25Entry zone — fair-value band

$22.90Published — price the day we called it

$27.94Target — the price the thesis aimed for

$24.17Peak — highest point inside the window, not a realized return

$20.75Window close — end-of-window price, context only

What happened

Partial

Reached 25% of the predicted growth at its peak, without hitting the target.

At window close

-9.4%

realized, from the publication price to the last close inside the window

Peak gain

+5.5%

peak, from the publication price — not a realized return

S&P 500, same window

+4.1%

SPY over the identical days, dividend-adjusted

Window close

$20.75

last close inside the window, ended August 11, 2026

Peak price

$24.17

peak on June 24, 2026 — not a realized return

Days to target

—

The thesis — published May 13, 2026

Predicted growth

+22%

over the measurement window

Target price

$27.94

the price the thesis aimed for

Entry zone

$22.00 – $23.25

the fair-value band we waited for

Price at publication

$22.90

published May 13, 2026

Confidence

72%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Innoviva earns steady fees from drug royalties instead of depending on one big drug success. A recent research note said those fees look durable and the company's cash position is solid. Trading is light and price moves can be sharp, but the current low price and recent pullback make a short-term rebound look plausible if risks hold.

Primary drivers

Steady royalty fees give predictable revenue
Research note supports the durability of royalties
Large cash balance lowers need for new financing
Thin trading and short interest can make price swings bigger

How it played out

INVA: the 22% rebound thesis missed

Lyra published a short-term thesis for a 22% rise from 22.90. The thesis pointed to steady royalty fees, research support for their durability, a large cash balance, and the potential for sharper moves because trading was thin and short interest was present.

INVA rose to a peak of 24.17 on June 24, a gain of 5.5%. It stayed below the 27.94 target throughout the window. By August 11, it had fallen to 20.75, below the publication price and the entry zone. The rebound thesis did not play out.

What happened during the window

On June 18, 2026, Innoviva's wholly owned subsidiary Nortiva Bio announced its launch to develop long-acting oral medicines. On August 11, 2026, Innoviva Specialty Therapeutics announced that three therapies had been named finalists for the 2026 Prix Galien USA award.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All INVA signals